These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36713761)

  • 1. Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories.
    Ishii M; Kaikita K; Yasuda S; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; Tsujita K;
    JACC Asia; 2022 Dec; 2(7):882-893. PubMed ID: 36713761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.
    Matoba T; Yasuda S; Kaikita K; Akao M; Ako J; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    JACC Cardiovasc Interv; 2021 Nov; 14(21):2330-2340. PubMed ID: 34736731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
    Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Am Heart J; 2021 Jun; 236():59-68. PubMed ID: 33657403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial.
    Matsuzawa Y; Kimura K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Hirayama A; Matsui K; Ogawa H;
    J Am Heart Assoc; 2021 Nov; 10(21):e020907. PubMed ID: 34658247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial.
    Kaikita K; Yasuda S; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2021 Nov; 14(11):e010476. PubMed ID: 34474583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings.
    Arashi H; Yamaguchi J; Hagiwara N; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Kimura K; Hirayama A; Matsui K; Ogawa H;
    Thromb Haemost; 2022 Sep; 122(9):1584-1593. PubMed ID: 35697255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trial.
    Noda T; Nochioka K; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; Yasuda S; Afire Investigators OBOT
    EuroIntervention; 2024 Apr; 20(7):e425-e435. PubMed ID: 38562065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
    Naito R; Miyauchi K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    JAMA Cardiol; 2022 Aug; 7(8):787-794. PubMed ID: 35704345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
    Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
    Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin versus P2Y
    Fukaya H; Ako J; Yasuda S; Kaikita K; Akao M; Matoba T; Nakamra M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Heart; 2021 Nov; 107(21):1731-1738. PubMed ID: 34261738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease.
    Ishii M; Kaikita K; Yasuda S; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Nishihara E; Nakamura S; Matsui K; Ogawa H; Tsujita K;
    Open Heart; 2023 May; 10(1):. PubMed ID: 37173099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study.
    Iijima R; Tokue M; Nakamura M; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    J Am Heart Assoc; 2023 Oct; 12(20):e031096. PubMed ID: 37815031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories.
    Barakat AF; Jain S; Masri A; Alkukhun L; Senussi M; Sezer A; Wang Y; Thoma F; Bhonsale A; Saba S; Mulukutla S
    JACC Clin Electrophysiol; 2021 May; 7(5):649-658. PubMed ID: 33812834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
    Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
    Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index.
    Kunadian V; Baber U; Pivato CA; Cao D; Dangas G; Sartori S; Zhang Z; Angiolillo DJ; Briguori C; Cohen DJ; Collier T; Dudek D; Gibson M; Gil R; Huber K; Kaul U; Kornowski R; Krucoff MW; Dehghani P; Mehta S; Moliterno DJ; Ohman EM; Escaned J; Sardella G; Sharma SK; Shlofmitz R; Weisz G; Witzenbichler B; Džavík V; Gurbel P; Hamm CW; Henry T; Kastrati A; Marx SO; Oldroyd K; Steg PG; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2022 Oct; 15(19):1948-1960. PubMed ID: 36202563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS).
    Ozaki Y; Kawai H; Muramatsu T; Harada M; Takahashi H; Ishii H; Maekawa Y; Ismail TF; Amano T; Izawa H; Murohara T
    Circ Rep; 2022 Dec; 4(12):604-608. PubMed ID: 36530841
    [No Abstract]   [Full Text] [Related]  

  • 20. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    Cho MS; Kang DY; Ahn JM; Yun SC; Oh YS; Lee CH; Choi EK; Lee JH; Kwon CH; Park GM; Choi HO; Park KH; Park KM; Hwang J; Yoo KD; Cho YR; Kim JH; Hwang KW; Jin ES; Kwon O; Kim KH; Park SJ; Park DW; Nam GB;
    N Engl J Med; 2024 Sep; ():. PubMed ID: 39225258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.